Botulinum Toxin B: Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Botulinum Toxin B
Therapeutic Class: Neurotoxin
Subclass: Neuromuscular Blocking Agent
Speciality: Neurology
Schedule (India): Schedule H
Route(s): Intramuscular (IM)
Formulations Available in India:
- Injection: 5,000 units/mL solution (0.5 mL vial — 2,500 units total)
- Injection: 5,000 units/mL solution (1 mL vial — 5,000 units total)
- Injection: 5,000 units/mL solution (2 mL vial — 10,000 units total)
Important Note: Botulinum Toxin B has very limited availability in India. Primarily imported on demand through specialty centres. Units are NOT interchangeable with Botulinum Toxin A products.
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Cervical Dystonia (Spasmodic Torticollis) — Adults
| Parameter | Recommendation |
|
Starting dose
|
2,500–5,000 units IM total, divided among affected neck muscles (sternocleidomastoid, splenius capitis, trapezius, levator scapulae) |
|
Titration
|
Increase by 2,500 units per session based on clinical response; minimum 12-week interval between sessions |
|
Usual maintenance dose
|
5,000–10,000 units per session every 12–16 weeks |
|
Maximum dose
|
15,000 units per session (some sources cite up to 25,000 units; specialist discretion) |
Clinical Notes:
- Primarily reserved for patients who develop neutralising antibodies to Botulinum Toxin A
- Faster onset of action (within days) but shorter duration compared to Type A
- Higher incidence of autonomic side effects (dry mouth)
- EMG guidance recommended for precise muscle targeting
- Response typically begins within 1 week; effect duration approximately 12–16 weeks
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Sialorrhoea (Parkinson’s disease, ALS, stroke)
|
1,500–3,500 units total divided between bilateral parotid glands (750–1,000 units each) and submandibular glands (250–500 units each) | Effect lasts 12–16 weeks; repeat as needed | OFF-LABEL; Specialist only (Neurology/ENT); Ultrasound-guided injection preferred; Evidence: International RCTs, limited Indian experience |
|
Focal Upper Limb Spasticity
|
1,500–10,000 units total distributed across affected muscles based on spasticity pattern | Repeat every 12–16 weeks | OFF-LABEL; Specialist only (PMR/Neurology); Evidence: International RCTs; Limited Indian data |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
NOT AVAILABLE in India — Botulinum Toxin B is NOT approved for paediatric use in India.
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Cerebral Palsy-related Spasticity
|
50–100 units/kg total divided across affected muscle groups | Repeat every 12–16 weeks | OFF-LABEL; Specialist only (Paediatric Neurology/PMR); Very limited experience; Extrapolated from international data |
Minimum Age: Not recommended below 16 years except under specialist supervision in tertiary centres with extensive experience.
Maximum Paediatric Dose: Lower of 10,000 units total OR 200 units/kg per session.
Safety Monitoring:
- Close observation for 48–72 hours post-injection
- Monitor for dysphagia, respiratory difficulty, generalised weakness
- Assess swallowing function before discharge
- Nutritional and growth monitoring with repeated use
Note: Botulinum Toxin A is preferred for paediatric indications due to greater experience and safety data.
RENAL ADJUSTMENT
- No dosage adjustment required
- Botulinum toxin acts locally at neuromuscular junction with negligible systemic absorption
- Use with caution in patients with significant renal dysfunction due to limited excretion data
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
No dose adjustment required |
|
Moderate impairment
|
No specific adjustment; use with caution |
|
Severe impairment
|
Use with caution; no hepatic metabolism but altered protein reserves may affect clinical response; specialist decision |
CONTRAINDICATIONS
- Known hypersensitivity to Botulinum Toxin B or formulation excipients (human albumin, sodium succinate, sodium chloride)
- Infection at proposed injection site
- Generalised disorders of neuromuscular transmission (myasthenia gravis, Lambert-Eaton myasthenic syndrome)
- Concurrent use of aminoglycosides or other agents interfering with neuromuscular transmission (delay botulinum injection)
CAUTIONS
- Pre-existing dysphagia or respiratory compromise — increased aspiration risk
- History of aspiration pneumonia
- Cardiovascular disease — autonomic effects (dry mouth, constipation) more pronounced with Type B
- Elderly patients — increased sensitivity to systemic effects
- Patients with pre-existing neuromuscular disorders (motor neurone disease, peripheral neuropathy)
- Previous exposure to any botulinum toxin — assess for antibody formation
- Concomitant use with anticoagulants — increased bruising risk at injection sites
- Repeated high-dose use — risk of neutralising antibody development
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Category C — Avoid unless clearly necessary |
|
Safety Data
|
No adequate human studies; animal studies show fetal toxicity at high doses |
|
Preferred Alternatives
|
Conservative management; Botulinum Toxin A has more safety data if botulinum therapy essential |
|
When May Be Used
|
Only for severe, debilitating dystonia unresponsive to other treatments; specialist decision only |
|
Monitoring
|
Fetal movement monitoring; ultrasound assessment if administered during pregnancy |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Not recommended during breastfeeding |
|
Expected Levels in Milk
|
Likely negligible due to large molecular size (150 kDa) and local action |
|
Preferred Alternatives
|
Botulinum Toxin A if treatment essential (more characterised); defer treatment if possible |
|
Infant Monitoring
|
If unavoidable: monitor feeding pattern, muscle tone, weight gain |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
Use lower end of dosing range (2,500 units for cervical dystonia) |
|
Titration
|
Slower titration; minimum 12-week interval; assess response before dose escalation |
|
Extra Risks
|
Increased sensitivity to autonomic effects (dry mouth, constipation, urinary retention); dysphagia risk; generalised weakness; falls risk |
|
Monitoring
|
Close observation for systemic effects; swallowing assessment mandatory for cervical injections |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, streptomycin)
|
Potentiate neuromuscular blockade; risk of respiratory compromise | Avoid concurrent use; delay botulinum if aminoglycoside therapy ongoing |
|
Non-depolarising muscle relaxants (vecuronium, atracurium, rocuronium)
|
Additive neuromuscular blockade | Avoid elective procedures requiring NMBAs within 2–4 weeks of botulinum injection |
|
Other botulinum toxin products (Type A or B)
|
Cumulative toxicity; unpredictable response | Do not administer different botulinum products concurrently or within close interval |
|
Spectinomycin, polymyxins, lincosamides (clindamycin)
|
Potentiate neuromuscular blockade | Avoid combination; if essential, monitor closely for weakness |
|
Magnesium sulphate
|
Potentiates neuromuscular effects | Caution in eclampsia management if botulinum recently administered |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Anticholinergics (oxybutynin, trihexyphenidyl, glycopyrrolate)
|
Additive anticholinergic effects (dry mouth, constipation, urinary retention); more pronounced with Type B | Monitor for anticholinergic toxicity; consider dose reduction of anticholinergic |
|
Muscle relaxants (baclofen, tizanidine)
|
Additive muscle weakness | Use with caution; monitor for excessive weakness |
|
Anticoagulants/Antiplatelets (warfarin, aspirin, clopidogrel)
|
Increased bruising at injection sites | Consider temporary hold if feasible; apply pressure post-injection |
|
Quinidine, quinine
|
May potentiate neuromuscular effects | Monitor for excessive weakness |
|
CNS depressants (benzodiazepines, opioids)
|
Additive sedation with systemic diffusion (rare) | Monitor in elderly; caution with high doses |
COMMON ADVERSE EFFECTS
- Dry mouth (very common with Type B; up to 30–40%)
- Dysphagia (especially with cervical injections; 10–25%)
- Injection site pain, erythema, bruising
- Neck pain or stiffness
- Headache
- Nausea
- Flu-like symptoms
- Taste disturbance
- Blurred vision (with periocular injections)
SERIOUS ADVERSE EFFECTS
- Generalised muscle weakness — rare; potentially life-threatening; requires immediate medical attention
- Respiratory compromise/failure — especially in patients with pre-existing respiratory disease or high doses
- Aspiration pneumonia — secondary to dysphagia; higher risk in elderly and cervical dystonia patients
- Systemic botulism-like syndrome — distant spread of toxin effect causing generalised weakness, respiratory difficulty
- Anaphylaxis/hypersensitivity reactions — rare; discontinue and treat as emergency
- Autonomic instability — rare; may require urgent management
Action Required: Discontinue immediately if generalised weakness, respiratory difficulty, or anaphylaxis occurs. Provide supportive care; hospitalisation may be required.
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Complete neuromuscular examination; document severity (TWSTRS for cervical dystonia); assess swallowing function (cervical indications); prior botulinum exposure history |
|
Post-injection (24–72 hours)
|
Observe for dysphagia, respiratory difficulty, generalised weakness; counsel patient/caregiver on warning signs |
|
Short-term (2–4 weeks)
|
Assess clinical response; document improvement in dystonia severity |
|
Long-term
|
Re-evaluate efficacy every 3–4 months; monitor for waning response suggesting neutralising antibody formation; reassess indication at each cycle |
BRANDS AVAILABLE IN INDIA
- Myobloc® (Solstice Neurosciences/US Worldmeds) — imported on demand; very limited availability
- NeuroBloc® (Eisai/Sloan Pharma) — European equivalent; rarely available in India
Note: Botulinum Toxin B products have very limited availability in India. Most specialists use Botulinum Toxin A products (Botox®, Dysport®, Xeomin®) as first-line. Type B is typically sourced through special import for refractory cases.
PRICE RANGE (INR)
| Formulation | Approximate Price | Notes |
| 2,500 units vial | ₹18,000–25,000 | Imported; price variable |
| 5,000 units vial | ₹30,000–45,000 | Limited supply |
| 10,000 units vial | ₹55,000–75,000 | Specialist procurement |
- Not included in NLEM; not under NPPA price control
- Available primarily through tertiary neurology centres and specialty import
- Significant price variability due to import costs
CLINICAL PEARLS
- Primary role in India: Reserved for patients with documented resistance (neutralising antibodies) to Botulinum Toxin A; not first-line therapy
- Unit non-interchangeability: Type B units are NOT equivalent to Type A units — do not attempt dose conversion; start fresh titration when switching
- Autonomic profile: Greater anticholinergic effects (dry mouth occurs in up to 40%) compared to Type A — warn patients and consider in elderly/those on anticholinergics
- Onset and duration: Faster onset (days vs weeks) but potentially shorter duration of action compared to Type A
- Antibody development: Patients who develop antibodies to Type A may also eventually develop antibodies to Type B with repeated use
- Storage: Store refrigerated at 2–8°C; do not freeze; once opened, use within 4 hours
TAGS
botulinum toxin B; rimabotulinumtoxinB; Myobloc; cervical dystonia; neurotoxin; Type A resistance; specialist-only; limited availability India; dry mouth; sialorrhoea
VERSION
RxIndia v0.2 — 03 Feb 2026
REFERENCES
- CDSCO import regulations for biologicals
- Indian Pharmacopoeia (botulinum toxins — general)
- AIIMS Neurology Department protocols
- Indian Movement Disorder Society recommendations
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
- Harrison’s Principles of Internal Medicine
- API Textbook of Medicine
- International RCTs — used for off-label indications only (sialorrhoea, spasticity)
- US FDA prescribing information for Myobloc (reference)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.